Cargando…
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
Since the first biosimilar medicine, Omnitrope(®) (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period between 2009 and 2019. Dr...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069914/ https://www.ncbi.nlm.nih.gov/pubmed/33918795 http://dx.doi.org/10.3390/ph14040348 |